Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials-Reference-Cited by-同舟云学术

Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials

Published:2023-12 Issue: Volume:386 Page:117354
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Landmesser Ulf,Koenig Wolfgang,Leiter Lawrence A.,Raal Frederick J.,Ray Kausik K.,Wright R. Scott,Han Jackie,Conde Lorena Garcia,Schwartz Gregory G.

Funder

Novartis

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference32 articles.

1. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study;Roth;J. Am. Coll. Cardiol.,2020

2. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010;Smolina;Circulation: Cardiovascular Quality and Outcomes,2012

3. Comparative analysis of recurrent events after presentation with an index myocardial infarction or ischaemic stroke;Yeo;Eur. Heart J. - Quality of Care and Clinical Outcomes,2017

4. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective;Jernberg;Eur. Heart J.,2015

5. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS);Mach;Eur. Heart J.,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Coding RNA Involved in the Pathogenesis of Atherosclerosis—A Narrative Review;Diagnostics;2024-09-07

2. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes;Journal of Clinical Medicine;2024-08-25

3. Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations;Current Opinion in Lipidology;2024-03-27

4. An update on inclisiran for the treatment of elevated LDL cholesterol;Expert Opinion on Pharmacotherapy;2024-03-03